Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000484537 | SCV000573784 | uncertain significance | not provided | 2019-08-15 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV001834575 | SCV003455427 | benign | Alpha thalassemia-X-linked intellectual disability syndrome | 2023-07-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002526967 | SCV003540464 | uncertain significance | Inborn genetic diseases | 2021-08-12 | criteria provided, single submitter | clinical testing | The c.3224A>G (p.D1075G) alteration is located in exon 9 (coding exon 9) of the ATRX gene. This alteration results from a A to G substitution at nucleotide position 3224, causing the aspartic acid (D) at amino acid position 1075 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001834575 | SCV002087309 | uncertain significance | Alpha thalassemia-X-linked intellectual disability syndrome | 2020-07-30 | no assertion criteria provided | clinical testing |